On January 8, 2021 Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, reported that it is participating in Biotech Showcase 2021 and will be presenting the strategic plan for long-term growth (Press release, Notable Labs, JAN 8, 2021, View Source [SID1234573699]). This year registered attendees to Biotech Showcase can access recorded company presentations prior to the actual event. On-demand access allows attendees to view presentations at their convenience, avoiding conflicts with busy meeting schedules during the main event week.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Laurie Heilmann, CEO will be presenting Notable Labs’ strategic vision at Biotech Showcase Digital.

"We are thrilled to share the strategic roadmap that will invigorate and accelerate growth for Notable over the next 3 years," said Heilmann. "This is our first invitation to present at Biotech Showcase and we are impressed at the level of partnership and visibility we have been able to achieve."

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

"We are delighted that Notable Labs will be presenting at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton. "Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery."

On January 8, 2021 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) reported that results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting (Press release, Dr Reddy’s, JAN 8, 2021, View Source [SID1234573698]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

On January 8, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that it will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, Feb. 11, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results (Press release, LabCorp, JAN 8, 2021, View Source [SID1234573695]). The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the conference call by dialing 1-877-898-8036 within the U.S. and Canada, or 1-720-634-2811 internationally, using the conference ID 7378794. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

An audio replay of the conference call will be available from 1:00 p.m. ET on Feb. 11, 2021, until 11:30 p.m. ET on Feb. 25, 2021, by dialing 1-855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the conference ID 7378794. The webcast of the conference call will be archived and accessible through Jan. 28, 2022, on the Labcorp Investor Relations website.

On January 8, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that it will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, Feb. 11, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results (Press release, LabCorp, JAN 8, 2021, View Source [SID1234573694]). The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the conference call by dialing 1-877-898-8036 within the U.S. and Canada, or 1-720-634-2811 internationally, using the conference ID 7378794. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

An audio replay of the conference call will be available from 1:00 p.m. ET on Feb. 11, 2021, until 11:30 p.m. ET on Feb. 25, 2021, by dialing 1-855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the conference ID 7378794. The webcast of the conference call will be archived and accessible through Jan. 28, 2022, on the Labcorp Investor Relations website.

On January 8, 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that it will hold its fourth-quarter and full-year 2020 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 4 (Press release, Merck & Co, JAN 8, 2021, View Source [SID1234573693]). During the call, company executives will provide an overview of Merck’s performance for the quarter.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at View Source A replay of the webcast, along with the sales and earnings news release, presentation and supplemental financial disclosures, will be available at www.merck.com.

Institutional investors and analysts can participate in the call by dialing (833) 353-0277 or toll free (469) 886-1947 and using ID code number 2268598. Members of the media are invited to monitor the call by dialing (833) 353-0277 or toll free (469) 886-1947 and using ID code number 2268598. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.